- Home
- COSM vs ATHA Comparison
COSM vs ATHA Comparison
Compare COSM & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- ATHA
- Stock Information
- Founded
- COSM 2009
- ATHA 2011
- Country
- COSM United States
- ATHA United States
- Employees
- COSM N/A
- ATHA N/A
- Industry
- COSM Other Pharmaceuticals
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- COSM Health Care
- ATHA Health Care
- Exchange
- COSM Nasdaq
- ATHA Nasdaq
- Market Cap
- COSM 19.4M
- ATHA 21.0M
- IPO Year
- COSM 2013
- ATHA 2020
- Fundamental
- Price
- COSM $0.86
- ATHA $0.53
- Analyst Decision
- COSM
- ATHA Buy
- Analyst Count
- COSM 0
- ATHA 4
- Target Price
- COSM N/A
- ATHA $11.25
- AVG Volume (30 Days)
- COSM 320.4K
- ATHA 235.4K
- Earning Date
- COSM 11-14-2024
- ATHA 02-20-2025
- Dividend Yield
- COSM N/A
- ATHA N/A
- EPS Growth
- COSM N/A
- ATHA N/A
- EPS
- COSM N/A
- ATHA N/A
- Revenue
- COSM $56,042,109.00
- ATHA N/A
- Revenue This Year
- COSM $4.53
- ATHA N/A
- Revenue Next Year
- COSM $25.00
- ATHA N/A
- P/E Ratio
- COSM N/A
- ATHA N/A
- Revenue Growth
- COSM 13.01
- ATHA N/A
- 52 Week Low
- COSM $0.47
- ATHA $0.41
- 52 Week High
- COSM $1.58
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- COSM 67.69
- ATHA 41.88
- Support Level
- COSM $0.51
- ATHA $0.52
- Resistance Level
- COSM $0.95
- ATHA $0.57
- Average True Range (ATR)
- COSM 0.08
- ATHA 0.04
- MACD
- COSM 0.02
- ATHA -0.00
- Stochastic Oscillator
- COSM 78.95
- ATHA 11.82
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.